Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain.

The published literature regarding ADRs in cancer patients after COVID-19 vaccine administration mostly shows an increasing trend of systemic ADRs after the second dose. 13 , 20 – 27 We could only find one study conducted in Thailand in which ADRs after the first and second of AZD1222 vaccine doses were evaluated observing the opposite trend. 28 Some articles have also showed an association between gender and the incidence of ADRs after the SARS-CoV-2 vaccines.

also in 63,971 other papers